Biogen (BIIB) Tops Q4 EPS by 8c; FY17 Rev Guidance Falls Below the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Biogen Reports 2016 Revenues of $11.4 Billion
January 26, 2017 6:30 AM EST2016 GAAP diluted EPS rise 10%; Non-GAAP diluted EPS rise 19%
Board of Directors Appoints Michel Vounatsos as Chief Executive Officer
SPINRAZATM Approved and Launched in the US for Spinal Muscular Atrophy
Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported full year and fourth quarter 2016 financial results, including:
Full year total revenues of $11.4 billion, a 6% increase versus the prior year. On a constant currency basis1, total... More